Bayer Pharma AG et al v. Cipla Ltd. et al
| Bayer Pharma AG, Bayer AG and Janssen Pharmaceuticals, Inc. |
| Cipla Ltd., Cipla USA Inc. and Invagen Pharmaceuticals, Inc. |
| 1:2023cv01196 |
| October 20, 2023 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on December 15, 2023. A more recent docket listing may be available from PACER.
| Document Text |
|---|
Filing 15
SO ORDERED Granting (D.I.158 in 21-cv-314-RGA-LDH; D.I. 14 in 23-cv-1196-RGA; D.I. 202 in 21-md-3017-RGA-LDH) Stipulation and Order Regarding Consolidation and Schedule: Civil Action 23-1196-RGA is consolidated with Civil Action 21 314-RGA-JLH for all purposes, including for trial. All papers shall be filed in Civil Action 21-314-RGA-JLH (see Order for further details). Signed by Judge Richard G. Andrews on 12/15/2023. Associated Cases: 1:21-md-03017-RGA-LDH, 1:21-cv-00314-RGA-LDH, 1:23-cv-01196-RGA(nms)
|
| Filing 14 STIPULATION and [Proposed] Order Regarding Consolidation and Schedule, by Bayer AG, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) Modified on 12/15/2023 (nms). |
|
SO ORDERED, re (D.I. 201 in 21-md-3017-RGA-LDH; D.I. 13 in 23-cv-1196-RGA) STIPULATION Extending Time to Respond to Complaint to December 22, 2023. Signed by Judge Richard G. Andrews on 12/14/2023. Associated Cases: 1:21-md-03017-RGA-LDH, 1:23-cv-01196-RGA(nms)
|
| Filing 13 STIPULATION Extending Time to Respond to Complaint to December 22, 2023 - filed by Cipla Ltd., Cipla USA Inc., Invagen Pharmaceuticals, Inc.. (Ferraro, April) Modified on 12/14/2023 (nms). |
|
Filing 12
SO ORDERED Granting (D.I. 197 in 21-md-3017-RGA-LDH; D.I. 11 in 23-cv-1196-RGA) Stipulation and Proposed Order Joining Invagen Pharmaceuticals, Inc. (Invagen Pharmaceuticals, Inc. added). Signed by Judge Richard G. Andrews on 11/21/2023. Associated Cases: 1:21-md-03017-RGA-LDH, 1:23-cv-01196-RGA(nms)
|
| Filing 11 STIPULATION and [Proposed] Order Joining Invagen Pharmaceuticals, Inc. by Cipla Ltd., Cipla USA Inc.. (Ferraro, April) |
| CORRECTING ENTRY: The stipulation filed at D.I. 11 on 11/17/2023, has been removed from the docket as its caption was deficient. This case is a member to MDL 21-3017-RGA-LDH, thereby requiring that it be captioned and filed in the MDL and the underlying civil action. Counsel is to correct the stipulation and refiled. (nms) |
| Filing 10 STIPULATION TO EXTEND TIME for Defendants Cipla Ltd and Cipla USA Inc. to answer, move, or otherwise respond to the Complaint in this action (D.I. 1) to December 14, 2023 - filed by Bayer AG, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) |
|
SO ORDERED, re (D.I. 10 in 23-cv-1196-RGA; D.I. 196 in 21-md-3017-RGA-LDH) STIPULATION to Extend Time for Cipla Ltd and Cipla USA Inc. to answer, move, or otherwise respond to the Complaint in this action to December 14, 2023. Signed by Judge Richard G. Andrews on 11/7/2023. Associated Cases: 1:21-md-03017-RGA-LDH, 1:23-cv-01196-RGA(nms)
|
| Filing 9 AFFIDAVIT of Service for Summons, Complaint and related papers served on Cipla Ltd. on October 24, 2023, filed by Bayer AG, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) |
| Filing 8 SUMMONS Returned Executed by Bayer Pharma AG, Janssen Pharmaceuticals, Inc., Bayer AG.Cipla USA Inc. served on 10/24/2023, answer due 11/14/2023. (Fahnestock, Derek) |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (nms) |
| Remark: MDL panel has been advised. (mkr) |
| Filing 7 Summons Issued as to Cipla Ltd. on 10/23/2023; and Cipla USA Inc. on 10/23/2023. (Attachments: #1 Summons Issued)(mkr) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bayer AG for Bayer Pharma AG filed by Bayer AG and Bayer Pharma AG. (mkr) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceuticals, Inc. filed by Janssen Pharmaceuticals, Inc. (mkr) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,828,310 B2. (mkr) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: On or about September 6, 2023. Date of Expiration of Patent: January 31, 2039.Thirty Month Stay Deadline: on or about March 6, 2026.(mkr) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mkr) |
| Filing 1 COMPLAINT for PATENT INFRINGMENT filed against Cipla Ltd. and Cipla USA Inc. (Filing fee $ 402, receipt number ADEDC-4254583.) - filed by Bayer Pharma AG, Janssen Pharmaceuticals, Inc., and Bayer AG. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet) (mkr) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
